Beijing InnoCare Pharma Tech Co.
9969 · HKEX
Public Market Listing
Live quotes, historical charts, and market capitalization for Beijing InnoCare Pharma Tech Co. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | CD19Monoclonal antibody | Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin Lymphoma Large B-Cell Lymphoma | |
| Phase 3 | TYK2Small molecule | Psoriasis | |
| Phase 3 | BCL-2Small molecule | Acute Myeloid LeukemiaMantle Cell LymphomaChronic Lymphocytic Leukemia | |
| Phase 3 | TYK2/JAK1Small molecule | Atopic DermatitisPsoriasis | |
| Phase 1/2 | Cereblon E3 ubiquitin-ligaseSmall molecule | Multiple Myeloma |
Upcoming events
(15 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
2027 (5)
March 2027 (2)
August 2027 (1)
What to watch
September 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (5)
2029 (2)
2030 (1)
November 2030 (1)
What to watch
2032 (1)
October 2032 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $76M | $33M | $1.1B | — | report ↗ |
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $330M | $132M | $1.1B | — | report ↗ |
InnoCare reported revenue of $330M (RMB 2,375M), up 135.3% YoY, with gross profit margin up 5.7 percentage points to 92%. R&D spend was $132M (RMB 952M), up 16.9% YoY, while cash and equivalents stood at $1,082M. Net income was $88.6M (RMB 644M), marking the company’s first annual profit, and it achieved positive operating cash flow for the first time.
Business highlights included two out-licensing deals, notably a Zenas agreement for orelabrutinib and autoimmune assets with total value exceeding US$2 billion, plus a Prolium agreement. Approvals included tafasitamab for R/R DLBCL, zurletrectinib for NTRK fusion-positive tumors, and orelabrutinib for 1L CLL/SLL with NRDL inclusion. Pipeline progress included completed Phase III enrollment for soficitinib in atopic dermatitis and ICP-488 in psoriasis, first dosing of the VAV1 degrader ICP-538, ongoing Phase I work for ICP-B794, and an IND submission for ICP-B208. Management’s strategic priorities include securing approvals for five to six innovative drugs, advancing three to four products globally, and progressing five to ten differentiated molecules into clinical trials.